GlassScriptPhysician profile
Melissa Bucklin
NPI 1285414730
$1,903.33
in general payments reported to CMS, 2019-2025
31 companies · $825 in 2025
The $825 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,079 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $266.12 | 2024-2025 | |
| Janssen Biotech, INC. | $194.84 | 2024-2025 | Tecvayli, Talvey, Erleada |
| Merck Sharp & Dohme LLC | $182.77 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $148.01 | 2024-2025 | Enhertu, Injectafer |
| Incyte Corporation | $91.93 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $85.45 | 2024-2025 | |
| Coherus Oncology, INC. | $85.04 | 2024-2025 | Udenyca, Loqtorzi |
| Astrazeneca Pharmaceuticals LP | $80.95 | 2024-2025 | Imfinzi |
| Eisai INC. | $73.21 | 2024-2025 | |
| Genentech USA, INC. | $72.63 | 2024-2025 | Tecentriq, Venclexta |
| Sumitomo Pharma America, INC. | $64.66 | 2024 | Orgovyx |
| Pfizer INC. | $57.72 | 2024 | |
| Pharmacosmos Therapeutics INC. | $53.33 | 2024-2025 | Monoferric |
| Tersera Therapeutics LLC | $44.41 | 2024-2025 | Quzyttir, Xermelo |
| Servier Pharmaceuticals LLC | $40.76 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $34.91 | 2025 | |
| Adc Therapeutics America, INC. | $31.65 | 2024-2025 | |
| Genmab U.S., INC. | $28.21 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.70 | 2025 | Fruzaqla |
| Beone Medicines USA, INC. | $25.87 | 2025 | Brukinsa |
| Astellas Pharma US INC | $23.85 | 2024 | Vyloy |
| Spectrum Pharmaceuticals INC. | $22.93 | 2024 | Rolvedon |
| Bard Peripheral Vascular, INC. | $21.59 | 2025 | Peritx |
| Lilly USA, LLC | $18.83 | 2025 | Verzenio, Jaypirca |
| Ipsen Biopharmaceuticals, INC | $18.62 | 2025 | Onivyde |
| Genzyme Corporation | $17.98 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.84 | 2024 | Opdivo |
| Myriad Genetic Laboratories, INC. | $16.68 | 2024 | Myrisk |
| Dendreon Pharmaceuticals LLC | $15.05 | 2025 | Provenge |
| Adaptive Biotechnologies Corporation | $14.38 | 2024 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bucklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.